Objective: To evaluate factors predicting efficacy, retention, and tolerability of add-on brivaracetam (BRV) in clinical practice. Methods: A multicenter, retrospective cohort study recruiting all patients who started BRV between February and November 2016 with observation time between 3 and 12 months. Results: Of a total of 262 patients (mean age 40, range 5-81 years, 129 male) treated with BRV, 227 (87%) were diagnosed to have focal, 19 (7%) idiopathic generalized and 8 (3%) symptomatic generalized epilepsy, whereas 8 (3%) were unclassified. The length of exposure to BRV ranged from 1 day to 12 months, with a median retention time of 6.1 months, resulting in a total exposure time to BRV of 1,504 months. The retention rate was 79.4% at 3 months and 75.8% at 6 months. Efficacy at 3 months was 41.2% (50% responder rate) with 14.9% seizure-free for 3 months and, at 6 months, 40.5% with 15.3% seizure-free. Treatment-emergent adverse events were observed in 37.8% of the patients, with the most common being somnolence, dizziness, and behavioral adverse events (BAEs). BAE that presented under previous levetiracetam (LEV) treatment improved upon switch to BRV in 57.1% (20/35) and LEV-induced somnolence improved in 70.8% (17/24). Patients with BAE on LEV were more likely to develop BAE on BRV (odds ratio [OR] 3.48, 95% confidence interval [CI] 1.53-7.95). Significance: BRV in broad clinical postmarketing use is a well-tolerated anticonvulsant drug with 50% responder rates, similar to those observed in the regulatory trials, even though 90% of the patients included had previously been exposed to LEV. An immediate switch from LEV to BRV at a ratio of 10:1 to 15:1 is feasible. The only independent significant predictor of efficacy was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure predicted poor psychobehavioral tolerability of BRV treatment. A switch to BRV can be considered in patients with LEV-induced BAE.
Antiepileptic drugs (AEDs) play a central and crucial role in the treatment of epilepsy patients, as most of these patients require anticonvulsant treatment for an extended period. Because up to 30% of patients are refractory to medical treatment, 1,2 the development of new therapeutic options is strongly warranted. Due to ongoing seizures, patients with drug-refractory epilepsy are affected by increased morbidity and mortality, social stigma, reduced employment opportunities, and impaired quality of life for both themselves and their caregivers. [3] [4] [5] [6] Introduction of a new AED provides an opportunity to achieve better seizure control for some patients. 7, 8 Brivaracetam (BRV) is the latest approved AED as adjunctive (add-on) therapy for the treatment of partialonset seizures, with or without secondary generalization, in adult and adolescent patients with epilepsy aged from 16 years of age. 9 It is a high-affinity synaptic vesicle protein 2A (SV2A) ligand that exceeds the binding potential of levetiracetam (LEV) by 10-to 30-fold. [9] [10] [11] [12] [13] [14] BRV showed promising results in clinical trials and had low discontinuation rates. 9 According to a smaller scope study in 29 patients, an immediate switch from LEV to BRV seems feasible without titration and might alleviate LEV-induced behavioral adverse events (BAEs). 15 The main treatmentemergent adverse events (TEAEs) observed during the regulatory trials were somnolence, dizziness and psychobehavioral symptoms. 9 However, results from regulatory clinical trials are difficult to extrapolate into clinical practice, as these studies are limited by their short duration, and rigid inclusion and exclusion criteria excluding most epilepsy patients, and lack of dosing flexibility. 16, 17 Upon introduction of new AEDs, there is limited information about the potential efficacy and tolerability in a naturalistic clinical setting. Therefore, it remains pivotal to assess new AEDs, such as BRV, in terms of their efficacy, tolerability and retention, a robust factor combining both, as well as quality of life and long-term safety, in a real-life setting.
Our multicenter study aimed to give insights into retention, efficacy, and tolerability in a large cohort of patients with different epilepsy syndromes during the first year of treatment with BRV. Furthermore, we tried to identify predictors of efficacy and tolerability and looked in detail into outcome and TEAEs in patients switched from LEV to BRV, and in patients with BAE during prior therapy with LEV, as there are only limited data available on these important patient subgroups.
Patients and Methods

Study settings and design
This retrospective study was performed at the university hospitals in Frankfurt am Main, Greifswald, and M€ unster. The study was granted approval by the ethics committee, and the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines were followed. 18 This study was not sponsored or funded by any company.
We reviewed the medical records of all epilepsy patients treated between February 15, 2016, and November 15, 2016 for prescription of BRV. Follow-up data were collected until February 15, 2017 to achieve at least 3 months of follow-up. All patients who were exposed to at least one dose of BRV were included. The only exclusion criterion was the lack of follow-up. Use of intravenous BRV in status epilepticus was reported separately. 19 The epilepsy diagnosis was based on the definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy. 20 The treating physician at each study site provided information on epilepsy syndrome, etiology, semiology, demographics, and concomitant and previous AEDs, with detailed history on the use of LEV, comorbidities, including modified Rankin Scale (mRS), 21 and the Charlson Comorbidity Index score. 22 Using a standardized reporting form we recorded starting, maintenance, and maximum doses of BRV, length of exposure to BRV, and withdrawal rates. Patients were interviewed about occurrence of TEAEs at each visit, and TEAEs were documented according to World Health Organization (WHO) criteria. Nonpsychotic BAEs, such as agitation, antisocial reaction, anxiety, apathy, depersonalization, depression, emotional lability, euphoria, hostility, nervousness, neurosis, and personality disorder, were recorded in detail, as described by Yates et al. 15 Patients were usually seen every 3-6 months. Frequency of seizures was obtained from medical notes and seizure diaries. Seizure frequency was recorded as an average per month for the last 3 months at baseline and at each follow-up for 3 and 6 months, if available. Retention rates were calculated for a 3 and 6-month period. Patients being seizurefree were defined as terminal remission of 3 months or more. Of the responses, 25%, 50%, and 75% were defined as a reduction in frequency of seizures of >25% (but <50%), and >50% and >75% during follow-up as compared to the 3-month baseline. No response was defined as a change in seizure frequency of <25%. Seizure increase was defined as increase in seizures of >25%. Two response rates were determined. Response rates were calculated for the first 3 months in all patients that started BRV, and for patients with a minimum of 6 months of follow-up. To ensure standardization, accuracy, and completeness, each patient's data were reviewed by the study coordinator (AS).
Data entry and statistical analysis
Statistical analyses were performed using IBM SPSS Statistics, Version 22.0 (IBM Corp, Armonk, NY, U.S.A.). Retention time on BRV was estimated using Kaplan-Meier survival curves, and the log-rank test was performed for comparison between patients switched from LEV and those not taking LEV prior to starting BRV. Chi-square tests were used for analysis of adverse events and the response of different clinical characteristics. Standard multiple regression analysis was used to identify independent predictors for ≥50% response and for tolerability, especially the occurrence of BAE at 3 months. We did not adjust the significance level according to multiple testing. All p-values were two sided and were regarded as statistically significant at <0.05.
Results
Patient characteristics at baseline
A total of 268 patients started BRV a minimum of 3 months before the end of the study period. There were no follow-up data on 6 patients, leaving 262 patients with at least 3 months of follow-up for further analysis. The mean age AE standard deviation (SD) at start of BRV treatment was 40.0 AE 16.0 years (median 38 years, range 5-81 years) and 129 patients were male (49.2%). Nine patients (3.4%) were children or adolescents <18 years, whereas 16 patients (6.1%) were ≥65 years of age. In total, 227 (87%) were diagnosed to have focal epilepsy (either structural/metabolic or cryptogenic), 19 (7%) idiopathic (genetic) generalized epilepsy (IGE), 8 (3%) symptomatic generalized epilepsy, and 8 (3%) were unclassified. The patients had a mean epilepsy duration of 21.6 AE 14.7 years (median 20 years, range 0.1-71 years) with epilepsy onset at a mean age of 18.4 AE 17.6 years (median 14 years, range 0.1-80 years). Disability, as measured by mRS, was present in 43 patients (mRS 3-5: 16.4%). Charlson Comorbidity Index showed no comorbidities in 203 patients (77.5%), whereas 59 patients had a score between 1 and 4 (22.5%), reflecting a low to moderate number of comorbidities. The patients were taking a mean number of 2.4 AE 0.9 AEDs (median 2, range 1-6 AEDs) before starting BRV. LEV (n = 133, 50.4%, mean dose 2,397 mg), lamotrigine (n = 84, 32.1%, mean dose 363 mg), lacosamide (n = 53, 20.2%, mean dose 347 mg), valproate (n = 51, 19.5%, mean dose 1,392 mg), zonisamide (n = 33, 12.6%, mean dose 326 mg), oxcarbazepine (n = 26, 10%, mean dose 1,460 mg), and topiramate (n = 24, 9.2%, mean dose 308 mg) were the most frequently prescribed drugs before initiation or switch to BRV. Strong enzyme inducers were prescribed only in 26 patients (10%), whereas 163 patients (62%) were taking a sodium channel blocker. In the past, the patients had failed a mean number of 4.4 AE 3.8 AEDs (median 4, range 0-17 failed AEDs, current AEDs not included), and only 26 patients (10%) were not exposed to LEV during their lifetime. Nonmedical therapy was used in 23 patients (8.8%) with vagus nerve stimulation (VNS) in 18, transcutaneous VNS in 4 and deep-brain stimulation of the anterior thalamus in one patient. Epilepsy surgery had been performed in 27 patients. The patients had an overall mean seizure frequency of 25.0 AE 47.9 seizures per month (median 7, range 0-405) during the 3-month baseline phase, and eight patients had been seizure-free during the 3 month baseline prior to start of BRV. Switch of therapy was mainly due to TEAEs on LEV in these patients. A subgroup of 113 patients (43.5%) had generalized tonic-clonic seizures (GTCS) at a frequency of 4.4 AE 7.8 per month (median 1.5, range 0.3-60).
Treatment with brivaracetam
The initial daily dose of BRV in patients not on LEV (n = 129) varied between 10 mg and 200 mg (mean 55.8 AE 27.7 mg, median 50 mg), with 50 mg/day being the most frequent (n = 81; 62.8%). The target dose ranged between 50 mg and 200 mg (mean 128.1 AE 49.2 mg, median 100 mg) and was achieved within a median time of 7 days.
Patients on LEV were switched to BRV (n = 133) at a median ratio of 15:1 (mean 14.8:1; range 2:1 to 40:1). The median ratio was significantly lower in patients on an LEV daily dose of 2,000 mg or less (median 10:1, mean 11.6:1, range 2:1 to 40:1) compared to patients on a daily LEV dose exceeding 2,000 mg (median 15:1, mean 17.9:1, range 9:1 to 40:1; p < 0.001). The switch was performed directly from one dose to the next in 105 cases within a median of 1 day; in 28 cases, a switch was performed in an overlapping fashion within a median of 12 days. The initial dose ranged between 25 mg and 400 mg (mean 125.2 AE 77.9 mg, median 100 mg) with 50 mg/day (n = 38; 28.6%), 100 mg/day (n = 37; 27.8%), and 200 mg/day (n = 34; 25.6%) being the most frequent initial BRV doses. The target dose ranged between 50 mg and 400 mg (mean 175.7 AE 60.0 mg, median 200 mg). There were no TEAEs associated specifically with direct versus overlapping switch from LEV to BRV. Overall, treatment with BRV was started with tablets in 248 patients (94.7%), with oral solution in 4 patients (1.5%), and via intravenous route in 10 patients (3.8%).
Outcome and predictors of response at 3 months
The probability of remaining on BRV treatment for all patients was 79.4% at 3 months. Discontinuation rate did not differ between patients started on BRV (n = 24/129, 18.6%) or switched from LEV (n = 31/133; 23.3%; p = 0.36). Discontinuation in 55 patients (21.0%) within the first 3 months was due primarily to insufficient efficacy (n = 30; 11.5%) and adverse events (n = 24; 9.2%); in one patient, BRV was discontinued due to pregnancy and one patient died due to glioblastoma. Of the 207 patients continuing BRV at a follow-up of 3 months, 108 (41.2%, 108/262 as per intention-to-treat analysis considering all patients that started BRV) reported 50% reduction in seizures, including 39 seizure-free patients (14.9%, 6 of them were seizure-free at baseline); 17 (6.5%) had <50% reduction and 12 (4.6%) had an increase in seizures, whereas, in 70 patients (26.7%), seizure frequency was unchanged. Regarding the 113 patients experiencing GTCS, 51 (45.1%) reported 50% reduction of GTCS, including 22 (19.5%) patients free of GTCS, seven (6.2%) with <50% reduction, and six (5.3%) with an increase in GTCS, whereas, in 29 (25.7%), frequency was unchanged. Among patients with IGE, six had persisting absences and eight had myoclonia before start of BRV; one of them had both. All patients with absences were responders at 3 months, whereas this was the case in only three patients with myoclonia (two discontinued, three nonresponders). Seizure response according to clinical characteristics is reported in Table 1 .
In comparing patients with >25% seizure reduction (n = 125; 47.7%) to patients who either discontinued during the first 3 months, were nonresponders or had increase in seizure frequency (n = 137; 52.3%), none of the following significantly affected the response rate of >25% seizure reduction: gender (HR: 0.99, 95% confidence interval [CI] 0.78-1.24), age (HR 0.93, 95% CI 0.74-1.17), epilepsy duration (HR 0.85, 95% CI 0.64-1.13), epilepsy syndrome (HR 0.79, 95% CI 0.46-1.36), etiology (HR 0.90, 95% CI 0.70-1.14), or number of failed AEDs (HR 0.90, 95% CI 0.71-1.14). A low number of concomitant AEDs (1 AED vs. ≥2 and more AEDs; HR 1.46, 95% CI 1.12-1.90) and start of BRV in patients not currently taking LEV (HR 1.36, 95% CI 1.05-1.76) was associated with response at 3 months. The latter was found to be an independent predictor in a standard multiple regression analysis (p = 0.045).
Long-term follow-up and retention analysis
The length of exposure to BRV ranged from 1 day to 12 months, with a median retention time of 6.1 months, resulting in a total exposure time to BRV of 1,504 months. Retention time, defined as the probability of remaining on treatment with BRV, was assessed using Kaplan-Meier survival curves for all patients (Fig. 1A) and depending on switch from LEV to BRV (Fig. 1B) . The retention between both groups did not differ (log-rank p-value: 0.83). The daily dose of BRV at last follow-up varied between 50 mg and 400 mg (mean 168.6 AE 71.5 mg, median 200 mg) with 27 patients taking a daily dose exceeding 200 mg.
A follow-up of at least 6 months was available in 192 patients. The probability of remaining on BRV was 75.8% at 6 months. Regarding seizure outcome, 77 (40.5%, 77/ 192 as per intention-to-treat analysis considering all patients that started BRV) reported 50% reduction in seizures, including 29 seizure-free patients (15.3%, 2 of them seizure-free at baseline), 13 (6.8%) having had <50% of reduction, and 4 (2.1%) with an increase in seizures, whereas, in 50 patients (26.3%), seizure frequency was unchanged. Regarding patients experiencing GTCS (n = 92) at 6 months, 41 (44.5%) reported 50% reduction, including 19 (20.7%) patients who were free of GTCS, 8 (8.7%) having had <50% reduction and 5 (5.4%) reporting an increase, whereas, in 38 (41.3%), frequency of GTCS was unchanged.
Treatment-emergent adverse effects
Treatment-emergent adverse effects (TEAEs) were reported in 99 patients (37.8%). The most frequent were sedation in 42 patients, dizziness in 31, mood changes in 24, headaches in 12, nausea and vomiting in 11, irritability in 11, and aggression in 10. All reported TEAEs are listed in Table 2 . During the study period, 68 patients of 262 discontinued BRV; 10 mg tablets were not used for downtitration in any of these cases. Intolerable TEAEs leading to discontinuation were sedation in eight patients, dizziness in eight, mood change in five, and nausea or vomiting in three patients; further details are presented in Table 2 . Of note is one patient who developed an allergic reaction with hypotension upon first infusion of BRV, and one adolescent (16 years) who developed a hyperpigmentation of both upper limbs following treatment with BRV for >6 months. In another patient, skin rash was probably due to carbamazepine exposure in the presence of a HLA-A*31:01 haplotype. 23 We observed two pregnancies, with exposure to BRV of 2 days in one case and approximately 6 weeks in a second case, during the first term. In both patients, BRV treatment was stopped and they were immediately switched to LEV. Both pregnancies are ongoing.
Regarding laboratory testing, we did not observe any serious derangements. In 12 patients (4.6%), there were mild liver enzyme elevations of not more than two-to three fold of the upper limit of the normal range and, in seven patients (2.7%), mild leukocytopenia (above 3/nl) or mild thrombocytopenia (above 100/nl) was recorded. We saw elevation of serum concentration of phenytoin in one and carbamazepine-epoxide in another patient.
Use of BRV in patients with adverse events on LEV
In total, 51 patients using LEV and reporting adverse events were switched from LEV (mean daily dose 2,107.8 AE 976.3 mg, median 2,000 mg) to BRV (mean daily dose 174.5 AE 48.4 mg, median 200 mg) at a median 
(18)
>200 mg/day 18 38.9 (7) 11.1 (2) 27.8 (5) (17) 13.3 (8) 16.7 (10) 15.0 (9) 16.7 (10) Idiopathic/cryptogenic 111 22.6 (24) 4.7 (5) 21.7 (23) 2.8 (3) 16 (17) 12.3 (13) 19.8 (21) BRV, brivaracetam; LEV, levetiracetam.
Epilepsia, 58 (7) In total, 57 patients reported current (n = 35) and previous (n = 22) BAE associated with exposure to LEV. Psychosis in one and suicidal ideations in another patient had been present while on LEV. Start or switch to BRV resulted in BAE in 13 (22.8%) of these patients, whereas this was the case in only 14 (7.8%) of patients who did not develop BAE while on LEV; for details, please refer to Table 3 . The likelihood of developing BAE was 3.5 times higher in patients with BAE on LEV (odds ratio [OR] = 3.48, 95% CI 1.53-7.95; p = 0.004). Gender, age, epilepsy duration, epilepsy syndrome and etiology did not predict development of BAE on BRV. Behavioral TEAEs on BRV were reported in 15.4% (4/26) of patients never exposed to LEV.
Discussion
Our study reflects the experience during the first year after market access of BRV in a cohort of 262 patients with different epilepsy syndromes, variation in seizure burden, and comorbidities. Ninety percent of the cohort had already been treated with LEV and 24% of these (57/236) had previously experienced or had ongoing BAE while on LEV.
Efficacy with 50% responder rates of 41.2% (14.9% seizure-free) for 3 months and 40.5% (15.3% seizure-free) for 6 months are on the upper end of what was observed during the randomized, double-blind controlled trials (RCTs). 24 This is somewhat surprising, considering that Epilepsia, 58 (7):1208-1216, 2017 doi: 10.1111/epi.13768 most patients were currently being or had been treated with LEV and that previous LEV exposure was reported to be associated with lower responder rates. 24, 25 Three of these phase III studies (N01252 26 20/50/100 mg/day; and N01253 25 5/20/50 mg/day; N01358 27 100/200 mg/day) applied fixed-dose regimens and included only patients with focal epilepsies, whereas one study (N01254 28 ) was designed for treatment with individual doses (20 mg-150 mg/day) and comprised patients with focal (90%) and generalized (10%) epilepsies. These RCTs showed 50% responder rates between 32.7% and 55.8% for 50 mg/day, 36-38.9% for 100 mg/day, and 37.8% for 200 mg/day, respectively. Treatment of our patients with idiopathic generalized epilepsies resulted in a 50% responder rate of 52.6% (10/19), pointing to a similar response in this patient subgroup. Such a high responder rate in patients in which generalized epilepsy syndromes were observed support previous publications in suggesting a role for BRV in treating generalized epilepsy syndromes. 28 Given that there was no dose-dependent increase in 50% responder rate in these RCTs, a ceiling effect has to be taken into account. 9 In clinical practice, uptitration of newly added AEDs is common practice and we dosed BRV to a mean dose 168.6 AE 71.5 mg (median 200 mg) at last follow-up, with 27 patients exceeding 200 mg. Therefore, BRV underdosing in our study can be excluded. The only independent significant predictor of efficacy at three months was the start of BRV in patients not currently taking LEV. Previously, historical seizure frequency and prior AED count were reported significant positive predictors of response in patients receiving BRV, which was not unique among AEDs.
Retention rates of 79.4% at 3 months and 75.8% at 6 months are comparable with other AEDs licensed in the last decade, such as lacosamide (80% at 6 months, 62-68% at 1 year), 29, 30 zonisamide (62% at 1 year), 31 perampanel (60% at 6 months), 32 or eslicarbazepine acetate (80-82% at 6 months, 72% at 1 year). 33 We observed a rather stable withdrawal rate over 12 months, at least in the patients without prior LEV, in comparison to the asymptotic curve with decreasing withdrawal rates reported for other AEDs in retention studies. 30, 34, 35 Retention rates did not differ between patients switching from LEV to BRV and patients started on BRV without intake of LEV. There were no specific adverse events seen with immediate switch from LEV to BRV (n = 105); therefore, such a practical approach seems feasible and not associated with increased risk of seizures. The median dose ratio used in patients with a daily dose of LEV 2,000 mg and below was 10:1, and 15:1 in patients exceeding 2,000 mg of LEV. At 3 months, it could be observed that more patients were nonresponders or discontinued BRV when they were switched from LEV. This effect was not seen at later follow-up and might reflect clinical decision-making for swift discontinuation after initial immediate switch to a relatively high dose, wherein a target dose of 175.7 mg (median 200 mg) was already administered for 3 months. In this patient group, it may be easier to distinguish responders from nonresponders at an early point in time than in those patients with no LEV intake at the time when BRV is started. In the latter patient group, it is more likely to use uptitration of BRV at 3 months and then to discontinue BRV at 6 months in case of no effect, as shown by Kaplan-Meier survival curves (Fig. 1B) . However, one limitation of our study is the rather limited follow-up <12 months.
BRV was relatively well tolerated, with a low rate of TEAEs of 37.8% in our study. Discontinuation due to adverse events occurred in 9.2% of the patients at 3 months. The most frequent TEAEs were somnolence, dizziness, and BAE, as observed in the RCTs. 9, [25] [26] [27] [28] Serious adverse events that occurred in phase II and phase III RCTs, and which were rated as possibly or probably related to BRV treatment, included prolonged somnolence, a psychotic episode, and convulsions. 9 In our study, we twice observed the occurrence of psychotic symptoms and one patient with suicidal ideation. One patient died due to glioblastoma diagnosed before start of BRV. Because electrocardiography (ECG) or laboratory testing was not routinely performed in a prospective fashion, this might have led to underestimation of cardiac or laboratory TEAEs. Sporadic cases of sinus bradycardia appeared in some of the RCTs. A well-designed phase I study using moxifloxacin (n = 52) as a positive control showed no effect of BRV 75 mg/day b.i.d. (n = 39) or 400 mg/day b.i.d. (n = 40), given over 6.5 days, versus placebo (n = 53) on cardiac repolarization in healthy subjects. 36 Because all patients were followed by specialist epilepsy services, it is unlikely that major or important adverse events were missed. However, given that we have a retrospective design, we cannot exclude the possibility of underdetection of TEAEs. BAE were closely followed-up and we analyzed occurrence depending on intake of LEV and BEA during treatment with LEV. In patients who experienced BAE while on LEV, starting BRV resulted in BAE in 13 (22.8%) of these patients, while this was the case in only 14 (7.8%) of patients who did not develop BAE while on LEV. The likelihood of developing BAE was 3.5 times higher in patients with BAE on LEV (OR = 3.48, 95% CI: 1.53-7.95; p = 0.004); however, use of BRV in patients that developed BAE on LEV is justified, as >75% will not develop BAE. Patients never previously exposed to LEV seem to have an intermediate risk of developing BAE in 15.3% (4/26) of the cases. The amelioration of BAE due to switch from LEV to BRV has already been studied in an open-label, prospective, exploratory study. 15 Patients underwent an immediate switch from LEV 1-3 g/day to BRV 200 mg/day without titration. Subsequently, the BRV dose was decreased somewhat in 7 (24%) of 29 patients. In total, 29 patients were enrolled and clinically meaningful reductions in BAE were seen in 27 (93%) of 29 patients. We can partly confirm these findings, as we saw BAE improved in 20 (57.1%)of 35, whereas, an aggravation was seen in 2 cases (5.7%). Furthermore, sedation attributed to treatment with LEV improved in 17 cases (70.8%) of 24, whereas it increased in 2 cases (8.3%). Therefore, patients who experience BAE or somnolence associated with LEV should be offered a switch to BRV.
Conclusions
We conclude that surprisingly high 3-and 6-month responder rates can be achieved using BRV in clinical practice, even in a cohort wherein 90% of patients had been previously exposed to LEV. This was unexpected, as prior use of LEV was previously reported to be associated with lower responder rates. The only independent significant predictor of efficacy at 3 months was the start of BRV in patients not currently taking LEV. The occurrence of BAE during previous LEV exposure was a significant predictor of a higher likelihood for psychobehavioral side effects with BRV treatment. However, BRV appears to be a useful option for patients experiencing BAE associated with LEV, and immediate switching appears feasible. The high responder rates in patients in which generalized epilepsy syndromes were observed, support previous publications in suggesting a role for BRV in treating generalized epilepsy syndromes.
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